BMEA

NASD Biomea Fusion Inc

Oct 9, 2026 · 9:23 AM ET LAST TRADE Market Closed

$1.37 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.37

YTD change: +10.48%
vs 20-day SMA: -8.76%
vs 200-day SMA: -3.11%

Price ranges

Previous day

$1.30 $1.38

open $1.32 close $1.37

+$0.05 (+3.79%)

Today

$0.00 $0.00

$1.37

Past week

$1.22 $1.38

from $1.30 now $1.37

+$0.07 (+5.38%)

Past month

$1.22 $1.93

from $1.70 now $1.37

-$0.33 (-19.41%)

This year

$1.03 $2.24

from $1.24 now $1.37

+$0.13 (+10.48%)

Price & Performance

-0.48 (-25.95%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral

The stock is 96.9% away from all-time highs of $43.69
BMEA is up 10% since the beginning of the year
BMEA is down 23% over the past 12 months
BMEA is down 19% over the past 1 month
21% of all BMEA investors are betting against BMEA

BMEA reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is -23.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.12

Earnings momentum +45.5% Quarterly EPS growth

Quarterly change +45.5%

Valuation

P/E ratio N/A

Enterprise value $64.8M

Beta 1.59

Balance sheet & scale

IncomeN/A

RevenueN/A

Cash$35.2M

Debt$877.0

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $99.3M

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Competitor comparison

Ticker	Company	Price	Change
AMGN	Amgen Inc.	$407.44	-1.37%
MRNA	Moderna, Inc.	$197.00	+0.26%
RVMD	Revolution Medicines, Inc.	$188.12	-6.35%
ROIV	Roivant Sciences Ltd.	$34.21	-1.55%
BNTX	BioNTech SE Sponsored ADR	$92.06	-3.35%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.